www.fdanews.com/articles/178144-pfizer-to-buy-astrazeneca-antibiotics-for-up-to-15-billion
Pfizer to Buy AstraZeneca Antibiotics for Up to $1.5 Billion
August 26, 2016
Pfizer struck an agreement with AstraZeneca to acquire the company’s late-stage small molecule anti-infectives business, which operates primarily outside of the United States, for up to $1.5 billion.
The deal includes upfront, milestone and sales-related payments of up to $1.34 billion as well as an additional close-of-transaction deferred payment of $175 million in January 2019.
The acquired portfolio comprises the drugs Zavicefta, Merrem, and Zinforo and two candidates in clinical development, ATM-AVI and CXL.
The parties expect the deal to close in the fourth quarter.